Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2022-08-25 Director's Dealing
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Mandatory notification of trade
Director's Dealing Classification · 100% confidence The document is titled "Mandatory notification of trade" and explicitly states that a transaction was completed by a primary insider (a board member) involving the purchase of company shares. This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for this is DIRS.
2022-08-25 English
Second quarter 2022 report
Investor Presentation Classification · 98% confidence The document is titled "Q2 22 Presentation" and contains slides detailing company highlights, product portfolio, market analysis, progress updates (specifically on NT-proBNP), and profiles of the management team and new board members. The content structure (slides, bullet points, financial targets, product pipeline review) is characteristic of an Investor Presentation (IP) or a presentation given during an earnings call or investor day. Since it is explicitly a 'Presentation' covering quarterly performance ('Q2 22') and strategy, the most appropriate classification is Investor Presentation (IP). It is not a formal regulatory filing like 10-K or IR, nor is it just an Earnings Release (ER) which is typically a short press release.
2022-08-25 English
Second quarter 2022 report
Earnings Release Classification · 99% confidence The document explicitly states it contains "Second quarter and first half year 2022 results" and provides detailed operational summaries, sales figures, market development updates, and product development progress for the first half of the year (1H22) and the second quarter (2Q22). This structure and content are characteristic of a comprehensive financial report covering a period shorter than a full fiscal year. Therefore, it aligns best with the Interim / Quarterly Report definition (IR). It is not an Earnings Release (ER) because it is comprehensive, not just highlights, and it is not the Annual Report (10-K). Since the document is long and detailed, it is the report itself, not a Report Publication Announcement (RPA). Q2 2022
2022-08-25 English
Second quarter 2022 report
Earnings Release Classification · 98% confidence The document explicitly announces 'results for the second quarter and first half of 2022' and provides key financial highlights (e.g., 'Record sales of MNOK 30.1 in 2Q22'). This content structure—a brief announcement summarizing period results, followed by a webcast invitation—is characteristic of an Earnings Release (ER). It is not the comprehensive report itself (which would be an IR or 10-K), nor is it a general regulatory filing (RNS) or a report publication announcement (RPA), as it contains the actual results summary. The length (3415 chars) supports this being a summary announcement rather than a full report. Q2 2022
2022-08-25 English
Gentian Diagnostics signs distribution agreement for Cystatin C
Regulatory Filings Classification · 100% confidence The document is a short press release dated August 23, 2022, announcing that Gentian Diagnostics has signed a distribution agreement for its Cystatin C Immunoassay with a global diagnostics company. This announcement pertains to a commercial partnership and business development, not a mandatory financial filing (like 10-K, ER, or IR). It does not fit the definitions for AGM-R, AR, MANG, CT, CAP, DVA, DLST, DIRS, SR, XLSX, FS, CGR, IRAT, IP, LTR, TAR, MRQ, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. Since it is a specific business update that doesn't fit the primary categories, it is best classified as a general Regulatory Filing (RNS), which serves as a broad category for non-standard announcements, although it is essentially a press release about a commercial agreement.
2022-08-23 English
Invitation to presentation of second quarter results
Report Publication Announcement Classification · 97% confidence The document is titled 'Invitation to presentation of second quarter results' and explicitly invites participants to a webcast for the second quarter 2022 results presentation scheduled for August 25th. This is not the full earnings release (ER) or the interim report (IR) itself, but rather an announcement about the upcoming presentation/call where those results will be discussed. Since the document is very short (554 chars) and serves to announce the timing and access method for a results presentation, it fits best under Report Publication Announcement (RPA), as it announces the event where the results will be shared, or potentially a Call Transcript (CT) if it were the transcript itself, but here it is an invitation. Given the context of announcing an event related to results, RPA is the most appropriate fit for an announcement about the release/presentation event.
2022-08-18 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.